Home › Funds › Slate Path Capital LP › NAMS

Slate Path Capital LP position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Slate Path Capital LP reported holding 319,000 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$10.8M, representing 0.15% of its reported portfolio and ranking #38 among its reported holdings. Slate Path Capital LP has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)319.00K sh
Reported value held$10.81M
Portfolio Weight0.15%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Slate Path Capital LP's NAMS position evolved

Slate Path Capital LP first disclosed a stake in NAMS in Q4 2024 at 319,000 shares (US$8.2M). The position peaked in Q4 2025 at 319,000 shares, worth US$11.2M. Across 7 filings, Slate Path Capital LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 319,000 shares valued at US$10.8M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 319.00K $8.20M New
Q1 2025 319.00K $6.53M Hold
Q2 2025 319.00K $5.78M Hold
Q3 2025 319.00K $9.07M Hold
Q4 2025 319.00K $11.19M Hold
Q1 2026 319.00K $10.21M Hold
Q2 2026 319.00K $10.81M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Slate Path Capital LP held NAMS?

Slate Path Capital LP has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Slate Path Capital LP's current position in NAMS?

As of Q2 2026, Slate Path Capital LP holds 319.00K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $10.81M, representing 0.15% of its reported portfolio and ranking #38.

Has Slate Path Capital LP been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Slate Path Capital LP held unchanged its position in NAMS. The position peaked in Q4 2025 at 319.00K shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.